WO2001002552A2 - Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives - Google Patents

Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives Download PDF

Info

Publication number
WO2001002552A2
WO2001002552A2 PCT/EP2000/006171 EP0006171W WO0102552A2 WO 2001002552 A2 WO2001002552 A2 WO 2001002552A2 EP 0006171 W EP0006171 W EP 0006171W WO 0102552 A2 WO0102552 A2 WO 0102552A2
Authority
WO
WIPO (PCT)
Prior art keywords
human
animal
protein
sequence
vector
Prior art date
Application number
PCT/EP2000/006171
Other languages
English (en)
Other versions
WO2001002552A3 (fr
Inventor
Hugo Alfons Gabriel Geerts
Koenraad Frederic Florentina Spittaels
Chris Van Den Haute
Freddy Kamiel Van Leuven
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915574.9A external-priority patent/GB9915574D0/en
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to JP2001508325A priority Critical patent/JP2003504015A/ja
Priority to AU62673/00A priority patent/AU782281B2/en
Priority to CA002372742A priority patent/CA2372742A1/fr
Priority to IL14740600A priority patent/IL147406A0/xx
Priority to NZ515956A priority patent/NZ515956A/en
Priority to EP00949241A priority patent/EP1216297A2/fr
Publication of WO2001002552A2 publication Critical patent/WO2001002552A2/fr
Publication of WO2001002552A3 publication Critical patent/WO2001002552A3/fr
Priority to NO20020010A priority patent/NO20020010L/no
Priority to US11/243,412 priority patent/US20060168673A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Definitions

  • the present invention relates to cell and animal models for a disease condition and in particular to an animal model which can function as a model for neurodegenerative diseases, such as Alzheimers.
  • Alzheimers disease is a neurodegenerative disorder which is the most prevalent form of senile dementia, with approximately 5% of individuals of 65 and 20% of those over so being afflicted.
  • the disease is characterised by the appearance of two principal lesions within the brain termed neurofibrillary tangles and senile plaques.
  • Neurofibrillary tangles are intracellular inclusion bodies which comprise filamentous aggregates of paired helical filaments (PHF) .
  • PHF paired helical filaments
  • the principal component of PHF has been shown to be Tau, a microtubule associated protein involved in stabilising the cytoskeleton and in determining neuronal shape.
  • Tau is a phosphoprotein and aberrant hyper phosphorylation of Tau appears to represent one mechanism for its aggregation into PHF.
  • FTDP-17 Fronto- temporal dementia associated with Parkinson's disease
  • Cortico-basal degeneration progressive supranuclear palsy, multiple system atrophy
  • Pick' s disease Dementia Pugilistica, Dementia with tangles only, dementia with tangles and calcification, Down syndrome, Myotonic dystrophy, Niemann Pick's disease type C, Parkinsonism-dementia complex of Guam, Postencephalic Parkinsonism, Prion diseases with tangles, subacute sclerosing panencephalitis .
  • the present invention is therefore directed to providing an animal model of neurodegenerative diseases, such as Alzheimers and which model may be utilised to identify compounds useful in treating or ameliorating the symptoms of the condition.
  • the present invention provides a nucleic acid vector comprising a) a nucleic acid sequence encoding a human Tau protein; b) a sequence capable of directing expression of said Tau protein in the nervous system of said animal; and c) a sequence which facilitates integration of said vector into the genome of said animal so as to prevent functional expression of said animal Tau protein in favour of said human Tau protein.
  • This construct or vector thus permits generation of cells of non human animals which express the human Tau and which are substantially uncontaminated with endogenous Tau proteins from the animal or cell.
  • a cell or non-human animal may be particularly useful as a model to monitor the function of human Tau proteins and its potential role in the progression of neurodegenerative disorders mediated by Tau protein, such as Alzheimer's disease.
  • the sequence which facilitates integration of the vector into the genome comprises a sequence of nucleotides which exhibits a sufficient degree of homology with the Tau sequence of the animal or the flanking regions thereof, to permit homologous recombination and subsequent insertion of the vector into the genome of said animal at a location which disrupts the coding region and hence expression of the endogenous Tau in said animal in favour of the human Tau protein encoded from the sequence present on said vector.
  • the vector of the invention may be targeted to, for example, the corresponding Tau sequence of a mouse by the inclusion of a Ncol restriction fragment suitable for insertion of the vector into the unique Ncol site in exon 1 of the Tau sequence in the mouse genome, although as aforementioned a range of appropriate regions of homology to sites upstream or downstream of said Tau sequence may be used.
  • An expression vector according to the invention includes a vector having a nucleic acid according to the invention operably linked to regulatory sequences, such as promoter regions, that are capable of effecting expression of said DNA fragments.
  • the term "operably linked” refers to a juxta position wherein the components described are in a relationship permitting them to function in their intended manner.
  • Such vectors may be transformed into a suitable host cell to provide for expression of a polypeptide according to the invention.
  • the invention provides a process for preparing receptors according to the invention which comprises cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the receptors, and recovering the expressed receptors.
  • the vector according to the invention is termed a
  • such a vector further comprises a marker sequence which in one embodiment may comprise the hygromycin marker gene Pgk-hyg.
  • the sequence encoding the Tau protein is preferably a cDNA sequence, and even more preferably encodes one of the Tau 40 isoforms already known in the art (Goedert M, Trends Neuroscience 1993 Nov; 16(11): 460-465). However, although the known sequences encoding human Tau isoforms may be utilised, mutated Tau sequences may be used to investigate the role of Tau protein in the pathology of neurodegenerative disorders in an animal mediated by Tau protein.
  • a second aspect of the invention comprises a further nucleic acid vector comprising (a) a nucleic acid sequence encoding a protein capable of modulating a human Tau protein; (b) a sequence capable of directing expression of said protein in the cells of said animal; and (c) a targeting sequence capable of facilitating integration of said vector into the genome of said animal optionally at a position corresponding to a sequence in said animal equivalent to said protein capable of modulating human Tau protein, so as to prevent expression of said equivalent sequence in favour of said protein capable of modulating human Tau protein.
  • Such a vector when integrated at said equivalent sequence in the animal genome, in a similar fashion to the vector described above, permits expression of the protein capable of modulating Tau protein in favour of the related or equivalent protein in said animal.
  • the sequence capable of directing expression of said human Tau protein or the modulator thereof is preferably a transcriptional control sequence which can steer expression of the proteins to the nervous system of the non-human animal.
  • Transcriptional control sequences according to the invention comprise a suitable promoter and other regulatory regions, such as enhancer sequences, that can modulate the activity of the promoter.
  • a bacterial expression vector may include a promoter such as the lac promoter and for transcription initiation in the Shine-Dalgarno sequence and the start codon AUG.
  • a eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome.
  • Such vectors may be obtained commercially or assembled from the sequences described by methods well known in the art.
  • a promoter refers to the region of DNA that is upstream with respect to the direction of transcription of the transcription initiation site and which promoter is in a relationship permitting expression of the relevant proteins according to the invention.
  • DNA sequences that drive expression to neurons are known. They include both control systems that are neuron-specific and control systems that are more or less promiscuous but that induce high levels of expression in neurons. Depending on the nature of the construct used in the production of the transgenic animal and, in particular, the control elements, the desired proteins may be expressed in all neurons or only in restricted subsets of neurons of transgenic animals. Neuron-specific control systems, that drive expression to neuronal cell types in general, are known. They may be derived from genes encoding neuron-specific proteins. Such systems may be used to bring about expression of the desired Tau protein and/or the protein capable of it's modulation, in neurons .
  • the sequence is a promoter which directs expression of said proteins in the neurons of the brain or other such cells including astrocytes, oligodendrocytes microglia or Schwann cells.
  • the promoter is the mouse Thy-1 promoter which drives expression in mouse central neurons.
  • the vector according to this aspect of the invention may, advantageously, be used in combination with the vector incorporating the sequence encoding the human Tau protein described above to transfect a non-human animal and thus provide a transgenic animal which serves as a model permitting investigation into the interactions between the protein capable of modulating human Tau protein and said Tau protein and identification of potential therapeutic agents capable of modulating the effects of the phosphorylation of Tau.
  • transgenic animal incorporating the nucleic acid vector encoding said human Tau protein may be crossed with another transgenic animal comprising the vector encoding said protein capable of modulating human Tau protein which may result in offspring which express both of the proteins.
  • the human sequences introduced into the transgenic animals may encode those which are known in the art.
  • the human Tau comprises a human Tau isoform already known in the art.
  • the sequence may have been subject to a mutation, such as for example, a point mutation which may simulate a mutation that gives rise to certain genetic diseases.
  • a mutation such as for example, a point mutation which may simulate a mutation that gives rise to certain genetic diseases.
  • the protein capable of modulating human Tau protein is a kinase, and preferably one which is capable of phosphorylating human Tau protein , such as human GSK-3 ⁇ kinase, for example.
  • GSK-3 ⁇ glycogen synthase kinase-3 ⁇
  • GSK- 3 ⁇ As a potential protein Tau and neurofilament kinase has been obtained in transfected cells, wherein both protein Tau (Lovestone et al., 1994; Anderton et al., 1995; Lovestone et al., 1996; Lovestone and Reynolds, 1997) and NF-H were identified as substrates.
  • Cotransfection of GSK-3 ⁇ with Tau in CHO cells increased its phosphorylation concomitant with loss of prominent bundles of microtubules (Wagner et al . , 1996), while co-transfection with NF-H in COS cells caused electrophoretic mobility retardation and the appearance of phosphate-dependent antibody profiles.
  • GSK-3 ⁇ The involvement of GSK-3 ⁇ in the hyperphosphorylation of Tau, both in cultured neurons and in vivo in brain, was indirectly supported by the finding that lithium, as inhibitor of GSK-3 ⁇ , caused Tau dephosphorylation at the sites recognized by antibodies Tau-1 and PHF- 1, which are two of the major epitopes typically associated with PHF in AD brain.
  • the physiological role of GSK-3 ⁇ was proposed to be in stabilizing the neuronal cytoskeleton by controlling phosphorylation of Tau and neurofilament-H and eventually other substrates (Takahashi et al., 1994).
  • GSK- 3 ⁇ plays a role in the development of the brain of
  • Xenopus as part of the Wingless signaling pathway in which the kinase is a negative regulator of dorsoventral axis formation.
  • phosphorylation of ⁇ -catenin mediated by axin or conductin, controls the degradation of ⁇ -catenin by the ubiquitin-proteasome pathway (Aberle et al., 1997; Behrens et al. 1998; Ikeda et al., 1998).
  • the model is particularly useful to investigate the molecular basis for Alzheimers and other neurodegenerative disorders mediated by Tau protein and to investigate compounds which may alleviate the symptoms of the disease.
  • the vectors may be transformed into a suitable host cell which is preferably eukaryotic, which may itself be used to transform a non-human animal.
  • a suitable host cell which is preferably eukaryotic, which may itself be used to transform a non-human animal.
  • the invention provides a process for preparing human Tau protein or a protein capable of modulating Tau protein, comprising cultivating a host cell transformed or transfected with a vector according to the invention, under conditions to provide for expression by the vector of said proteins, and recovering the expressed proteins.
  • the host cell is a non-human animal cell, and even more preferably, an embryonic cell of a non-human animal .
  • incorporation of the exogenous DNA into the genome of the animal is accomplished by electroporation of the vector in embryonic stem cells.
  • the cells that have the exogenous DNA incorporated into their genome by homologous recombination may subsequently be injected into blastocysts for generation of the transgenic animals with the desired phenotype.
  • Successfully transformed cells which contain the vector according to the invention may be identified by well known techniques, such as lysing the cells and examining the DNA by, for example, Southern blotting or using the polymerase chain reaction.
  • the vectors may be, for example, plasmid, virus, cosmid or phage vectors, and may contain one or more selectable markers such as the hygromycin marker gene Pgk-hyg.
  • the present invention also advantageously provides nucleic acid sequences of at least approximately 10 contiguous nucleotides of a nucleic acid according to the invention and preferably from 10 to 50 nucleotides even more preferably, the nucleic acid sequence comprise the sequences illustrated in Table 1. These sequences may, advantageously be used as probes or primers to initiate replication, or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting for the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.
  • the probes according to this aspect of the invention may be anchored to a solid support. Preferably, they are present on an array so that multiple probes can simultaneously hybridize to a single biological sample.
  • the probes can be spotted onto the array or synthesised in si tu on the array. (See Lockhart et al . , Nature Biotechnology, vol. 14, December 1996 "Expression monitoring by hybridisation to high density oligonucleotide arrays".
  • a single array can contain more than 100, 500 or even 1,000 different probes in discrete locations.
  • the nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as for example using PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 10 to 50 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified region or fragment and recovering the amplified DNA.
  • PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 10 to 50 nucleotides to a region of the gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified region or fragment and
  • the nucleic acids or oligonucleotides according to the invention may carry a revealing label.
  • Suitable labels include radioisotopes such as 32 P or 35 S, enzyme labels or other protein labels such as biotin or fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques per se.
  • Antisense technology can be used to control gene expression through triple-helix formation of antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA.
  • the 5' coding portion or the mature protein sequence, which encodes for the protein of the present invention is used to design an antisense RNA oligonucleotide of from 10 to 50 base pairs in length.
  • a DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee et al . Nucl. Acids Res.,
  • the antisense RNA oligonucleotide hybridises to the mRNA in vivo and blocks translation of an mRNA molecule (antisense - Okano, J. Neurochem. , 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)).
  • each of the relevant proteins may be inhibited using antisense technology which may be used to selectively confirm the action of candidate compounds which may be identified as potential treatments for Alzheimers or other neurodegenerative diseases mediated by Tau protein using the transgenic non-human animal described herein, which expresses said human Tau and/or said protein capable of modulating human Tau protein.
  • antisense technology which may be used to selectively confirm the action of candidate compounds which may be identified as potential treatments for Alzheimers or other neurodegenerative diseases mediated by Tau protein using the transgenic non-human animal described herein, which expresses said human Tau and/or said protein capable of modulating human Tau protein.
  • the vectors of the invention may include a stop signal or sequence between the sequence capable of directing expression of said human Tau or the protein capable of modulating human Tau protein, which stop signal is flanked by two loxP sites.
  • the vector is used to establish the transgenic line as described above and in the examples below, expression of the relevant protein will not occur unless the Cre recombinase protein is present.
  • the Cre protein catalyses reciprocal conservative DNA recombination between the pairs of loxP sites with the resulting excision of the stop sequence located between the loxP sites.
  • the Cre protein may itself be expressed in another transgenic animal which is mated with the first, to remove the stop sequence following the reciprocal combination event between the two loxP sites to switch on expression of the appropriate sequence in the transgenic animal.
  • This technique also permits the DNA sequence encoding the proteins according to the invention to be excised by the Cre protein by including in the appropriate nucleic acid vector loxP sites flanking the sequences encoding human Tau and/or the protein capable of modulating human Tau protein.
  • Such vectors can be used to investigate the role of null mutations or knock-outs of the sequences encoding the proteins in the transgenic animal according to the invention.
  • a defined nucleic acid includes not only the identical nucleic acid but also any minor base variations including in particular, substitutions in cases which result in such as for example a synonymous codon (a different codon specifying the same amino acid residue) due to the degenerate code in conservative amino acid substitutions.
  • nucleic acid sequence also includes the complementary sequence to any single stranded sequence given regarding base variations.
  • a further aspect of the invention comprises a method of making a transgenic non-human animal which expresses a human Tau protein comprising the steps of: (a) introducing into an embryo cell of said animal a nucleic acid vector according to the invention; (b) introducing the embryo from step (a) into a female animal; (c) sustaining the female in step (b) until such time as the embryo has sufficiently developed and is borne from the female; and (d) sustaining the transgenic animal.
  • a further method of generating a transgenic non-human animal which expresses a human Tau protein comprises the steps of (a) introducing sequentially or simultaneously into an embryo cell of said animal a nucleic acid vector comprising a transgene encoding said human Tau protein; and a nucleic acid vector comprising a sequence of nucleotides which upon integration into the genome of said animal are capable of preventing expression of endogenous Tau protein from said animal; (b) introducing the embryo from step (a) into a female animal; (c) sustaining the female in step (b) until such time as the embryo has sufficiently developed and is borne from the female; and (d) sustaining the transgenic animal.
  • Another method of generating a transgenic non-human animal which is a model for diseases such as Alzheimers disease comprises crossing a first transgenic non-human animal expressing human Tau protein from a vector according to the invention with a second transgenic non-human animal expressing a protein capable of modulating human Tau protein according to the invention, selecting among the progeny those that carry both expression of said human Tau protein and said protein capable of modulating human Tau protein.
  • the Cre/lox technology can be used to manipulate expression of the proteins in each of the transgenic non-human animals described herein by incorporation of loxP sites flanking an appropriate DNA sequence.
  • the sequence may be one or both of those encoding either human Tau or the protein capable of modulating human Tau protein themselves or alternatively a stop sequence or codon which prevents expression of the above proteins unless a recombination event occurs in the presence of Cre recombinase to remove the stop sequence.
  • the vectors used according to this aspect of the invention, to generate the transgenic non-human animals, are incapable of replication in yeast.
  • a further aspect of the invention comprises a transgenic non-human animal that is a model for Alzheimers disease or for another neurodegenerative disease, which animal comprises an introduced DNA sequence encoding and capable of expressing the protein Tau in the nervous system of said animal and also comprises a DNA sequence encoding and capable of expressing a protein capable directly or indirectly of modulating the human Tau protein.
  • the human Tau and the protein capable of modulating human Tau are preferably those encoded by the sequences on the vectors according to the invention as described above.
  • a further aspect of the invention comprises a method of generating a transgenic non-human animal which is a model for Alzheimers disease or related neurodegenerative disorders, comprising the steps of crossing a first transgenic non-human animal comprising a vector having, i) a nucleic acid sequence encoding a human Tau protein, ii) a sequence capable of directing expression of said human Tau protein in the nervous system of said animal and iii) a targeting sequence which facilitates integration of said vector into the genome of said animal, with a second transgenic non-human animal comprising a vector capable of expressing a protein capable of modulating human Tau protein according to the invention, selecting among the progeny those that express both human Tau protein and said protein capable of modulating human Tau protein.
  • transgenic non-human animal is also provided by crossing a first transgenic non-human animal expressing human Tau protein with another non-human animal transgenic for the protein which modulates human Tau protein. Therefore, according to this aspect of the invention there is provided a method of generating a transgenic non-human animal which is a model for Alzheimers disease or related neurodegenerative disorders, comprising the steps of crossing a first transgenic non-human animal comprising a vector having, i) a nucleic acid sequence encoding a human Tau protein, ii) a sequence capable of directing expression of said human Tau protein in the nervous system of said animal and iii) a targeting sequence which facilitates integration of said vector into the genome of said animal, with a second transgenic non-human animal comprising a vector according to the invention, selecting among the progeny those that express both human Tau protein and said protein capable of modulating Tau protein.
  • progeny or "offspring” is intended to include the resulting product of a mating between the transgenic animals described provided it carries a vector according to the invention. Also included are germ cells from said transgenic animals which may themselves be used to produce further offspring comprising a vector according to the invention stably integrated into its genome.
  • the non-human animal used in accordance with the methods of the invention is a mammal and even more preferably a mouse.
  • the nucleic acid vectors described can be introduced into the embryonic stem cells, by for example electroporation. Microinjection of the cells is performed on the embryo when it is at the one cell stage, thus ensuring that the nucleic acid vector will be incorporated into the germ line of the animal and thus be expressed in all cells of the animals for subsequent transmission to progeny.
  • a further aspect of the invention comprises progeny of the transgenic animal according to the invention, which progeny carries any of the nucleic acid vectors according to the invention stably integrated into their genome.
  • the transgenic animal may advantageously exhibit the symptoms of Alzheimer's or other related - 1 !
  • Compounds which modulate and interfere with (either by enhancing or inhibiting) the hyperphosphorylation of human Tau protein may be identified by administering the compounds to the animal.
  • Compounds identified as enhancers may advantageously be applied to the animal to enhance development of the disease.
  • Inhibitors of the disease may be identified by monitoring the effects or the phosphorylation profile of Tau protein in the animal following application or administration of the compound to the animal.
  • the compounds may be administered by any suitable route, such as orally or intravenously.
  • the present invention provides a method of producing a compound which modulates the human kinase mediated hyperphosphorylation of human Tau protein comprising the steps of any one of the above described screening methods; and additionally:
  • the compounds isolated by the above methods also serve as lead compounds for the development of analog compounds.
  • the analogs should have a stabilized electronic configuration and molecular conformation that allows key functional groups to be presented to the Tau protein or the kinase in substantially the same way as the lead compound.
  • the analog compounds have spatial electronic properties which are comparable to the binding region, but can be smaller molecules than the lead compound, frequently having a molecular weight below about 2 kD and preferably below about 1 kD.
  • Identification of analog compounds can be performed through use of techniques such as self-consistent field (SCF) analysis, configuration interaction (CI) analysis, and normal mode dynamics analysis.
  • SCF self-consistent field
  • CI configuration interaction
  • normal mode dynamics analysis normal mode dynamics analysis.
  • transgene not every vector, which may otherwise be referred to as a transgene, will function optimally in every cell or animal type. Thus, routine experimentation may be required to identify or establish the best kinase or Tau isoform or promoter sequence for any given cell or animal type.
  • Antibodies to the protein or polypeptide of the present invention may, advantageously, be prepared by techniques which are known in the art.
  • polyclonal antibodies may be prepared by inoculating a host animal, such as a mouse, with the polypeptide according to the invention or an epitope thereof and recovering immune serum.
  • Monoclonal antibodies may be prepared according to known techniques such as described by Kohler R. and Milstein C, Nature (1975) 256, 495-497.
  • such antibodies may be included in a kit for identifying the human Tau or the kinase in a sample, together with means for contacting the antibody with the sample.
  • Figure 1 is an illustration of the recombinant
  • DNA construct used to target the mouse Tau locus The triangles represent the loxP sites.
  • the black boxes indicate a part of the exon 1 of the mouse Tau gene.
  • BSSK+ denotes the bluescript cloning vector.
  • Pgk-hyg represents the hygromycin marker gene.
  • the middle figure shows a partial structure of the wild-type mouse Tau gene.
  • Nco 1 is the unique site on exon 1 into which the entire construct is introduced.
  • the lower figure shows the construct ready for introduction into the ES cells and if homologous recombination occurs in the mouse genome, the different probes used with different enzyme digestions. Details are in the text under the section.
  • Figure 2 is an illustration of the Southern Blot used to identify transgenic mice incorporating the human Tau 40 cDNA at the embryonic stage. 5 of the 46 pups injected at the embryonic stage contained the DNA.
  • Figure 3 is an illustration of a Western Blot results indicating a 64 kDa Tau protein in three different transgenic mouse strains, and probed with antibodies HT- 7 and Tau-5.
  • Figures 4 & 5 are illustrations of the different digestions using rare cutting restriction enzymes in a restriction map of the human Tau gene.
  • Figure 6 is an illustration of the expression of human GSK-3 ⁇ in brain of transgenic mice (A) and activity of human GSK-3 ⁇ in the brain of transgenic animals using a synthetic substrate peptide
  • Figure 7 is an illustration of the results of a Western Blot of brain extracts of GSK- 3 ⁇ [S9A] /htau40 double transgenic mice,
  • Figure 8 is an illustration of the method of producing the loxP - hygromycin construct. This construct is incapable of replication and/or of expressing exogenous proteins in yeast.
  • Figure 9 is a restriction digest of the construct of Figure 8 using various restriction enzymes.
  • Figure 10 illustrates a restriction map of the construct of Figure 8.
  • Figure 11 is an illustration of the results obtained by probing a cell line to ensure the presence of the constructs.
  • FIG 12 is an illustration of Western Blotting of brain extracts of GSK-3 ⁇ [S9A] transgenic mice of 7 months old. Each panel compares brain extracts from 2 individual wild type (wt) mice and from
  • FIG. 13 is an illustration of the effect of alkaline phosphatase pretreatment on hyperhosphoryled protein tau. Brain homogenates of single and double htau- 40-5 and GSK-3 ⁇ [S9A] /htau40 transgenic mice were either applied untreated, or after incubation at 37°C for 3 hours without or with alkaline phosphatase (0.5 unites per ⁇ l) prior to Wester Blotting. For staining with antibodies
  • Tau-5 and Tau-1 the amounts of extract applied were 6 times less than for blotting with AT-8 and AT-180. Note the reduction in signals and the increase in electrophoretic mobility as described and discussed in the text.
  • Figure 14 (a) and (e) are graphic representations of the recombinant DNA constructs used to generate transgenic mice that express a mutant form of GSK-3 ⁇ , denoted GSK3- ⁇ [S9A] and htau40; (b) and (c) are illustrations of the results obtained from a Western Blot of brain and spinal cord extracts from transgenic and wild type mice, illustrating expression of the transgene in the transgenic compared to the wild-type mice; (d) and (g) are illustrations of immunohistochemical localisation of the transgenic proteins in neuronal cell bodies and processes in the cortex and hippocampus in addition to motor neurons in the ventral horn of the spinal cord, expressing both the human GSK-3 ⁇ [S9A] mutant and the human tau transgene.
  • Figure 15 is an illustration of the results obtained from a Western Blot using brain extracts of double tau-4R x GSK- 3 ⁇ [S9A] transgenic mice of five weeks old immunoblotted using antibodies, AT-
  • Figure 16 is an illustration of the results obtained from binding experiments of tau protein to re-assembled microtubules extracted from mouse brain and spinal cord derived from htau-4R x GSK-3 ⁇ double transgenic mice compared with htau-4R littermates.
  • Figure 17 is an illustration of results obtained from Western Blots of human and murine tau protein which remained unbound to microtubules, using antibodies Tau-1, AT-180 and AD-2. Further shown are the results of quantitative analysis of the unbound protein by densitometric scanning and normalisation to the reaction with antibody Tau-5.
  • Figure 18 is an illustration of the results obtained from a Western Blot to demonstrate that AD-2 and 12E8 epitopes are differentially present on the bound and free protein tau in the microtubule extracts .
  • Figure 19 is an illustration of sections of diseased axons showing accumulation of synapthophysin-bearing vesicles in human tau transgenic animals.
  • Figure 20 is an illustration of sections of brain and spinal cord of double tau-4R x GSK- 3 ⁇ transgenic mice showing a dramatic reduction in the number of dilated axons and lack of muscle wasting in the quadriceps of htau 40-1 x GSK3 ⁇ mice.
  • Figure 21 is an illustration of the results obtained from evaluating the effect of co-expression of GSK-3 ⁇ on the motoric aspect of the phenotype in different tests in double htau 40 x GSK-3 ⁇ transgenic mice, relative to htau 40-2, GSK-3 ⁇ and Wild-type mice.
  • (a) is the result of the ⁇ uprighting reflex'
  • the human GSK-3 ⁇ protein was revealed by Western Blotting (Fig 6A) and was enzymatically active towards a GS-1 synthetic peptide. In brain homogenates of transgenic ice, GSK-3 ⁇ kinase activity was about doubled relative to the activity in wild-type mouse brain (Fig 6B) . Immunohistochemically, the human protein was localized in neuronal cell bodies and in processes in the cortex and hippocampus conform to and expected from the known expression pattern of the adapted mouse thyl gene construct used (Moechars et al., 1996 and references therein).
  • transgenic mice expressing the longest human tau- 4R isoform have been described and characterized (Spittaels et al, 1999) .
  • the present inventors have generated transgenic mice that express a mutant form of human GSK3B, denoted GSK- ⁇ [S9A] since the cDNA contained an alanine residue in position 9, instead of the wild-type serine to prevent inactivation by phosphorylation (Woodgett, 1990) .
  • the cDNA was incorporated in a recombinant DNA construct based on the mouse thy-1 gene promoter (Fig 14a) and transgenic mice were generated by micro- injection, in the FVB mouse strain (Moechars et al, 1996, 1999; Spittaels et al, 1999) .
  • the human GSK-3 ⁇ protein was demonstrated by Western blotting in brain and spinal cord (Fig 14b) .
  • the transgene was enzymatically active on a synthetic peptide substrate, resulting in a doubling of the total GSK-3 ⁇ kinase activity in GSK-3 ⁇ mouse brain homogenates, relative to wild-type mice (Fig 14c).
  • Immuno-histochemically, the human transgenic proteins were localized in neuronal cell bodies and in processes in the cortex and hippocampus (Fig 14d) , as expected for the adapted mouse thyl gene construct (Moechars et al., 1996, 1999; Spittaels et al, 1999).
  • motor neurons in the ventral horn of the spinal cord also expressed the human GSK-3 ⁇ [S9A] mutant and the human tau transgene as well (Fig 14d, g) (Spittaels et al, 1999) . Both transgenes were thus demonstrated to be expressed in the same neurons, in the same regions of brain and spinal cord.
  • Double transgenic mice were obtained by cross-breeding the single transgenic strains. Analysis of phosphorylation of protein tau
  • the epitopes of AD-2 and 12E8 encompass Ser 396 /Ser 404 (Buee-Scherrer et al., 1996) and Ser 262 /Ser 356 (Seubert et al., 1995), respectively, and have been discussed as pivotal in the tau-microtubule interaction, subject to regulation by phosphorylation (Bramblett et al., 1993; Sengupta et al., 1998). Our results suggest that phosphorylation of the AD-2 epitope, in our conditions by GSK-3 ⁇ , could indeed be essential for this interaction.
  • a pathological hallmark of the tau4R transgenic mice i.e. the presence of dilated axons (Spittaels et al., 1999) is now demonstrated to contain synapthophysin- bearing vesicles, normally rapidly transported to the synapse by the motor protein kinesin, which also accumulated in the diseased axons (Fig 19). Consequently, the excess protein tau appeared to inhibit axonal transport by binding to the microtubules in the tau4R transgenic mice, and this then caused the axonal dilatations and the axonopathy (Spittaels et al, 1999) .
  • WT denotes wild-type mice
  • n number of mice analyzed .
  • Murine protein tau extracted from the brain of young GSK- 3 ⁇ [S9A] transgenic mice was somewhat hyperphosphorylated, as manifested by the presence of isoforms with slower electrophoretic migration, with some AT-180 immunoreactivity but weak or absent AT-8 reaction on western blots.
  • endogenous protein tau isoforms with clearly retarded electrophoretic mobility and with strong AT-8 immuno-reactivity were evident in the brain. Isoforms of murine protein tau that migrated on 8% polyacrylamide gels as a broadened band, reacted with antibodies PHF-1 and Tau-5.
  • human protein tau40 containing 2 N-terminal inserts and 4 microtubule binding repeats. Using the same type of gene promoter construct assured the expression of both transgenes to coincide inside the same neurons in brain. In the single and double transgenic mice, human tau protein accounted for up to 60% of total protein tau in the brain of the highest expressing transgenic mouse line.
  • Immunodetection with HT-7 revealed a somatodendritic localisation in addition to axonal staining, similar to a previous report on human tau transgenic mice (Gotz et al. 1995), and resembling the localisation of endogenous protein tau in central neurons (Tashiro et al. 1997) .
  • the cDNA coding for human GSK-3 ⁇ [S9A] was ligated in the mouse thyl gene (Moechars et al., 1996).
  • a Pvul- Notl restriction fragment was micro-injected into 0.5 day old FVB/N prenuclear mouse embryos.
  • Transgenic founders were identified by southern blotting of Stul- restricted mouse tail-biopt DNA, hybridized with a probe of 701 bp obtained by PCR with forward primer 5'CAAGGTCCCCGTTTCTCC3' and reverse primer 5'CAGGGGATAGTGGTGTGG3' .
  • Human Tau40 was ligated in the mouse thyl gene.
  • a Pvul-Notl restriction fragment was micro-injected and transgenic founders identified by southern blotting of Stul-restricted mouse tail-biopt DNA.
  • the probe of 135 bp was obtained by PCR with forward primer 5' CCCCACCACAGAATCCA3 ' located in the mouse thyl gene and reverse primer 5' GCCCCCCTGATCTTTCC3' located in the human tau40 cDNA. Routine genotyping of transgenic offspring, bred into the FVB/N genetic background, was performed on tail-biopt DNA by PCR with a forward primer 5' CTGGGGCGGTCAATAAT3' located in the human tau40 gene and a reverse primer - 31
  • GSK-3 ⁇ [S9A] protein levels in brain extracts were estimated by Western Blotting with monoclonal antibodies TPK I/GSK-3 ⁇ (0.1 ⁇ g/ml) and htau40 protein levels with monoclonal antibodies HT-7 (0.5 ⁇ g/ml) and Tau-5 (0.5 ⁇ g/ml).
  • Kinase enzymatic activity was measured on brain homogenates after immunoprecipitation and fractionation by ion-exchange FPLC (Mono S) (Pharmacia, Uppsala, Sweden) (Van Lint et al. 1993) .
  • mice were anesthetized with nembutal and intracardially perfused with either paraformaldehyde (4% v/v) or methacarn (MC) (50% methanol, 30% chloroform, 10% acetic acid) . Brains were immersion-fixed overnight, dehydrated and embedded in paraffin (unless stated otherwise) . Microtome sections (6 ⁇ m) were dewaxed, hydrated and incubated with blocking solution, i.e. 3% BSA, 10% normal goat serum in Tris Buffered Saline (TBS) (50 mM Tris, pH7.4, 0.15 M NaCl).
  • blocking solution i.e. 3% BSA, 10% normal goat serum in Tris Buffered Saline (TBS) (50 mM Tris, pH7.4, 0.15 M NaCl).
  • brain sections were rinsed with 500 ⁇ l TBS (3x5'), incubated with biotin conjugated secondary antibody (1/1000) for one hour, washed (3x5') and pretreated with 500 ⁇ l 0.05 M Tris-HCl for 5 minutes.
  • tissue sections were submerged in 300 ⁇ l Strept-ABComplex/HRP (1 droplet of both solutions per 15 ml 0.05 ml 0.05 M Tris-HCl) for half an hour and successively washed (3x5'), pretreated with 500 ⁇ l 0.05 M Tris-HCl for 5' and stained with DAB.
  • brain tissue was homogenized in 2 ml of MES buffer with inhibitors, i.e. 0.1 M MES (pH 6.4), 0.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 ⁇ g/ml leupeptin, 5 ⁇ g/ml pepstain, 1 ⁇ M okadaic acid, 200 ⁇ M PMSF, 20 mM NaF, 200 ⁇ M sodium orthovanadate, 5 ⁇ g/ml soybean trypsin inhibitor, 1% Triton-X-100, 1% sodium desoxycholate and 0.1% SDS.
  • MES buffer with inhibitors i.e. 0.1 M MES (pH 6.4), 0.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 ⁇ g/ml leupeptin, 5 ⁇ g/ml pepstain, 1 ⁇ M
  • mice brain homogenates of GSK-3 ⁇ transgenic mice were incubated with immobilized protein-G (Pierce, Illinois, USA) at 4°C for 2.5 hours and purified from mouse IgG by centrifugation (8000 rpm, 5', 4°C). The supernatant was denatured and reduced prior electrophoretical separation.
  • brain homogenates were diluted in a dephosphorylation buffer (Boehringer Mannheim) containing alkaline phosphatase (Boehringer Mannheim, 0.5 unit/ ⁇ l homogenate) and gently stirred at 37°C for 3 hours. Samples to be loaded on the gel were prepared as mentioned above.
  • Antibodies HT-7 directed to human tau
  • AT-8 directed to phosphorylated Serl99 and/or Ser202 (Biernat et al. 1992)
  • AT-180 directed to phosphorylated Thr231 (Goedert et al. 1994) are purchased from Innogenetics, Gent, Belgium.
  • Anti- TPKI/ GSK-3 ⁇ was bought from Affinity, Nottingham, UK; Tau-5 (recognizing tau, phosphate-independent) from Beckton Dickinson, San Diego, CA; Tau-1 (directed to non-phosphorylated Serl99 and Ser202 (Biernat et al. 1992) from Boehringer Mannheim, Germany and biotin conjugated secondary antiserum from Biorad Labs, CA.
  • PHF1 directed to phosphorylated Ser396 and Ser404 (Otvos et al. 1994) was a gift of P. Davies .
  • the ES cell line E14 (Hooper et al., 1987) was cultured on mitomycin-treated STO fibroblasts, in Glasgow ME medium containing non-essential amino acids, 20% (w/v) fetal calf serum, 0. ImM 2- mercaptoethanol and ImM sodium pyruvate. Trypsinized ES cells (1.5-2 x 10 7 ) were resuspended in 500 ⁇ l of culture medium and electroporated with 10 to 15 ⁇ g of the linearised targeting DNA, using an electric pulser (Biorad Labs.) at settings of 200 V and 960 ⁇ F in electroporation cuvettes of 0.4 cm electrode distance.
  • an electric pulser Biorad Labs.
  • the electroporated ES cells were seeded onto mitomycin treated STO fibroblasts in 25 cm 2 flasks and 40 hours later, the medium was replaced with medium containing 100 ⁇ g/ml of Hygromycin B. Hygromycin resistant colonies were picked up 10 to 14 days later after electroporation and further expanded for genotyping.
  • DNA was isolated from the selected ES cell lines and 10 ⁇ g was digested with the desired restriction enzyme for 4 to 6 hours. The digests were separated by electrophoresis at 2 V/cm mechanism for 14 hours on 0.7% agarose gels resulting in an overnight run. The following day the gels were stained by Ethidium bromide and photographed, processed for capillary transfer to nylon membranes. After baking and pre- hybridisation, the blot was hybridised with the radiolabelled probes at a concentration of 2-5 x 10 r cpm/ml and kept overnight at 60°C. Hybridisation was carried out in 6X SSC, 5X Denhardt's solution, 1% SDS, 0.1% heparine, 10% Dextran sulphate and 0.1% Salmon Sperm DNA. Membranes were washed at 60°C for one hour in 0.3X SSC, 0.5% SDS and placed for autoradiographic exposure at 70°C.
  • DNA was transferred by capillary transfer to a nylon membrane with 10X SSC ( 1.5M sodium chloride, 150mM sodium citrate, pH 7.2). The membrane was baked for 2 hrs at 80°C, pre-hybridised for 6 hrs at 60°C in 6X SSC, 4X Denhardt's solution, 1% SDS, 100 ⁇ g salmon sperm DNA, 10% dextran sulfate and 0.05% heparin. Hybridisation was carried out overnight at 60°C in the same solution supplemented with 2-5 x 10 6 cpm/ml of the indicated [ 32 P] -labelled DNA probe.
  • 10X SSC 1.5M sodium chloride, 150mM sodium citrate, pH 7.2
  • the membrane was washed in 0.3X SSPE supplemented with 0.5% SDS for 1 hr at 60°C before autoradiographic exposure with intensifying screens at -70 C for 1-7 days .
  • the ThyI-Tau-40 probe as mentioned above, Hygromycin probe (a gift from Lieve Umans, Lutgarde Serneels and Anton Roebroek) and a 3' probe.
  • the latter was made by a BamHI-Kpn I restriction of a 13kb EcorV-Hind III fragment harbouring exon 1 and the intron between the exons 1 and 2 of the mouse Tau gene cloned in the Bluescript vector (gift by Hirokawa, 1997 ) yielding an external probe.
  • the 3' external probe thus obtained was purified from the gel and used for the first screening of the electroporated ES cells cultured on Hygromycin containing selection medium.
  • the Thyl probe used to check the 5' region of the construct is obtained by Apal digestion of the Thy I DNA (Prof .Van Der Putten) .
  • Brain tissues were homogenized in 2 ml of 0.1M MES Buffer pH 6.4, 0.5mM MgCl 2> 1mm EDTA, ImM EGTA, ImM DTT, 0.2mM PMSF, 20mM NaF, 0.2mM Na 3 V0 4 , l ⁇ M okadaic acid, 5 ⁇ g/ml leupeptin, 5 ⁇ g/ml pepstatin, 5 ⁇ g/ml soybean trypsin inhibitor, 1% sodium desoxycholate, 1% Triton-X-100 and 0.1% SDS (Genis et al., 1995, with minor modifications). The brain extract so obtained was denatured at 95°C for 10 min and separated on a 8% SDS-PAGE.
  • HT-7 monoclonal antibody BR-01, clone HT-7, Innogenetics
  • Tau-5 monoclonal antibody 60101A, Pharmigen
  • the purified PAC2 clone was characterised by the analyses of restriction fragments separated by Pulse Field Gel Electrophoresis (PFGE) and identified by Southern blotting using the probes generated by PCR (see materials and methods) .
  • PFGE Pulse Field Gel Electrophoresis
  • the results of the different digestions using rare-cutting restriction enzymes are shown on the restriction map of the human Tau gene ( Figure 4) .
  • the PAC2 clone as sized by PFGE was around 200 kb and housed the entire human Tau gene, confirmed by Southern blotting using different probes that identified the 5' , middle and 3' regions of the gene.
  • the linearised DNA was then purified using Qiagen columns and dialysis chambers [Millipore Purification columns, Spectra PorCE Dispodialyzer of Spectrum] of different pore sizes, of which we found the tip-20 column of QIAGEN the most efficient as it yielded DNA with least shearing and with a low elution volume a concentration of 1 ng/ ⁇ l was obtained, (one of the drawbacks of the dialyses membranes) which is required for microinjection.
  • Genotyping by PCR identified 2 out of 9 pups as the PAC2 human Tau gene founders. Although the PCR did show us results yet no expression was observed in these mice as studies by Western Blotting . Knockin-Knockout targeted vector
  • the loxP-PGK-hygromycin construct was cut out of the pGEM vector by Notl and ligated into the BamHI site of the Bluescript vector. Transformation of DH5 cells with this 4.7kb construct yielded two positive colonies out of the 20 screened. Restriction analyses with Sail and Seal enzymes gave the expected bands indicating that ligation occurred in the right orientation which was confirmed by sequencing with the T7 primer.
  • the 8 kb Thy-1 human Tau 40 construct (see materials and methods) with the loxP site was subcloned into the Smal site of the above bluescript vector. After transformation 5 out of the 20 colonies screened harboured the insert.
  • Ndel ⁇ 13.5kb, ⁇ 1.2kb, ⁇ 1.6kb
  • Figure 10 shows a restriction map of the concluded construct.
  • This construct is incapable of replicating and/or expressing the exogenous proteins in yeast.
  • This final construct was linearised with Notl and purified on a tip-100 column (Qiagen) which finally gave a concentration of 2.25 ⁇ g/ ⁇ l of which 8 ⁇ l was used for electroporation into ES cells.
  • the ES cells that survived the electroporation were grown on Hygromycin selective medium and after a fortnight well-grown 333 colonies had been picked up for culturing.
  • With the help of Southern blotting using the external 3' probe for the first screening (as mentioned in the materials and methods) , we were able to pick up 6 potential positive cell lines in the first screening.
  • the Thyl probe used After the second screening of these 6 colonies with the internal Hygromycin and Thyl Tau 40 probe we obtained one cell line that contained the right targeted construct in it. Besides, the Thyl probe used finally also confirmed the presence of the 5' region of the construct in the positive cell line ( Figure 11) and the 5' BamHI fragment hybridising with this probe measured the same number of base pairs as the predicted BamHI-fragment if the construct was homogonously recombined.
  • the marker used in the blots is a 1 kb marker.
  • This first positive cell line was used for injection into blastocysts while further screening has resulted in five more potential cell lines. Uterine transfers have so far given 20 pups from three female mice of which 6 are chimeric.
  • the switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region.
  • Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localization of the kinase. Neuroscience Letters 147:58-62.
  • Glycogen synthase kinase 3 ⁇ is identical to tau protein kinase I generating several epitopes of paired helical filaments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La présente invention concerne un acide nucléique vecteur comprenant : (a) une séquence nucléotidique codant une protéine Tau humaine ; (b) une séquence capable de diriger l'expression de la protéine Tau humaine dans le système nerveux d'un animal non humain ; et (c) une séquence de ciblage qui facilite l'intégration dudit vecteur dans le génome de l'animal afin d'empêcher l'expression de la protéine Tau équivalente ou d'une protéine liée ou équivalente de l'animal en faveur de la protéine Tau humaine. Dans un autre aspect, l'invention concerne un acide nucléique vecteur comprenant : (a) une séquence nucléotidique codant une protéine humaine capable de moduler la protéine Tau humaine ; (b) une séquence capable de diriger l'expression de la protéine précitée dans le système nerveux de l'animal ; et (c) une séquence de ciblage capable de faciliter l'intégration dudit vecteur dans le génome de l'animal facultativement en une position correspondant à une séquence dans l'animal codant un équivalent de la protéine humaine précitée, de façon à empêcher l'expression de la séquence équivalente en faveur de la protéine humaine capable de moduler la protéine Tau humaine. On utilise les vecteurs de l'invention pour fabriquer un animal transgénique non humain en (a) introduisant dans une cellule embryonnaire de l'animal un ou plusieurs acides nucléiques vecteurs décrits ci-dessus ; (b) en introduisant l'embryon de l'étape (a) précitée dans un animal femelle ; (c) en maintenant la femelle dans l'étape (b) jusqu'à ce que l'embryon se soit suffisamment développé et naisse ; et (d) en maintenant en vie l'animal transgénique obtenu.
PCT/EP2000/006171 1999-07-02 2000-06-30 Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives WO2001002552A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2001508325A JP2003504015A (ja) 1999-07-02 2000-06-30 神経変性疾患のモデルとしてのトランスジェニック動物
AU62673/00A AU782281B2 (en) 1999-07-02 2000-06-30 Transgenic animals as models for neurodegenerative disease
CA002372742A CA2372742A1 (fr) 1999-07-02 2000-06-30 Animaux transgeniques doubles utilises comme modeles dans les maladies neurodegenaratives
IL14740600A IL147406A0 (en) 1999-07-02 2000-06-30 Transgenic animals as models for neurodegenerative disease
NZ515956A NZ515956A (en) 1999-07-02 2000-06-30 Transgenic animals as models for neurodegenerative disease
EP00949241A EP1216297A2 (fr) 1999-07-02 2000-06-30 Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives
NO20020010A NO20020010L (no) 1999-07-02 2002-01-02 Transgene dyr som modeller for neurodegenerativ sykdom
US11/243,412 US20060168673A1 (en) 1999-07-02 2005-10-04 Transgenic animals as models for neurodegenerative disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9915574.9A GB9915574D0 (en) 1999-07-02 1999-07-02 Transgenic animals as models for neurodegenerative disease
GB9915574.9 1999-07-02
GBGB0002674.0A GB0002674D0 (en) 1999-07-02 2000-02-04 Transgenic animals as models for neurodegenerative disease
GB0002674.0 2000-02-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/243,412 Continuation US20060168673A1 (en) 1999-07-02 2005-10-04 Transgenic animals as models for neurodegenerative disease

Publications (2)

Publication Number Publication Date
WO2001002552A2 true WO2001002552A2 (fr) 2001-01-11
WO2001002552A3 WO2001002552A3 (fr) 2001-12-20

Family

ID=26243577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/006171 WO2001002552A2 (fr) 1999-07-02 2000-06-30 Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives

Country Status (8)

Country Link
EP (1) EP1216297A2 (fr)
JP (1) JP2003504015A (fr)
AU (1) AU782281B2 (fr)
CA (1) CA2372742A1 (fr)
IL (1) IL147406A0 (fr)
NO (1) NO20020010L (fr)
NZ (1) NZ515956A (fr)
WO (1) WO2001002552A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088109A2 (fr) * 2000-05-18 2001-11-22 Consejo Superior De Investigaciones Cientificas Modele de maladie neurodegenerative
WO2002063951A2 (fr) * 2001-02-09 2002-08-22 University Of Florida Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique
WO2002068663A1 (fr) * 2001-02-26 2002-09-06 Nv Remynd Modele de tau-opathie
WO2003046172A2 (fr) * 2001-11-09 2003-06-05 University College London Modele de maladie
WO2004007722A2 (fr) * 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Animal transgenique exprimant la proteine tau de la maladie d'alzheimer
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US8039209B2 (en) 2001-02-15 2011-10-18 The University Of Chicago Yeast screens for treatment of human disease
KR20150145201A (ko) 2014-06-17 2015-12-29 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5558049B2 (ja) * 2009-08-21 2014-07-23 泰造 谷口 非ヒトモデル動物を用いたパーキンソン症候群の検査方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005466A1 (fr) * 1993-08-12 1995-02-23 Institute Of Psychiatry Modeles de la maladie d'alzheimer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005466A1 (fr) * 1993-08-12 1995-02-23 Institute Of Psychiatry Modeles de la maladie d'alzheimer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BRION J-P ET AL: "TRANSGENIC EXPRESSION OF THE SHORTEST HUMAN TAU AFFECTS ITS COMPARTMENTALIZATION AND ITS PHOSPHORYLATION AS IN THE PRETANGLE STAGE OF ALZHEIMER'S DISEASE" AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 154, no. 1, January 1999 (1999-01), pages 255-270, XP000965124 ISSN: 0002-9440 *
BROWNLEES J ET AL: "TAU PHOSPHORYLATION IN TRANSGENIC MICE EXPRESSING GLYCOGEN SYNTHASE KINASE-3BETA TRANSGENES" NEUROREPORT,RAPID COMMUNICATIONS OF OXFORD, OXFORD,GB, vol. 8, no. 15, 20 October 1997 (1997-10-20), pages 3251-3255, XP000974561 ISSN: 0959-4965 cited in the application *
DAWSON, H.N. ET AL.: "Tau distribution in a human tau gene transgenic/mouse tau knock out model" SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, October 1999 (1999-10), page 790 XP001020341 & 29th Annual Meeting of the Society for Neuroscience, Miami Beach, Florida, USA October 23-28 1999 *
DAWSON, H.N. ETAL.: "Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice" JOURNAL OF CELLULAR BIOLOGY, vol. 114, no. pt 6, March 2001 (2001-03), pages 1179-1187, XP001020383 *
GÖTZ, J. ET AL.: "Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform" EMBO JOURNAL, vol. 14, no. 7, 3 April 1995 (1995-04-03) - 1304, page 1313 XP002175363 EYNSHAM, OXFORD GB cited in the application *
GUO Q, SEBASTIAN L, SOPHER BL, MILLER MW, WARE CB, MARTIN GM, MATTSON MP.: "Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid beta-peptide toxicity: central roles of superoxide production and caspase activation." JOURNAL OF NEUROCHEMISTRY, vol. 72, no. 3, March 1999 (1999-03), pages 1019-1029, XP001020319 *
HARADA A. ET AL.: "Altered microtubule organization in small-calibre axons of mice lacking tau protein" NATURE., vol. 369, no. 6480, 9 June 1994 (1994-06-09), pages 488-491, XP002175364 MACMILLAN JOURNALS LTD. LONDON., GB ISSN: 0028-0836 *
KÜHN ET AL: "Advances in gene targeting methods" CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD. LONDON, GB, vol. 9, 1997, pages 183-188, XP002133099 ISSN: 0952-7915 *
MICHEL GOEDERT & MASATO HASEGAWA.: "The Tauopathies Toward an Experimental Animal Model" AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 1, January 1999 (1999-01), pages 1-6, XP002923749 *
SAUER BRIAN: "Inducible gene targeting in mice using the Cre/lox system." METHODS, vol. 14, April 1998 (1998-04), pages 381-392, XP001019712 *
SPITTAELS K ET AL: "PROMINENT AXONOPATHY IN THE BRAIN AND SPINAL CORD OF TRANSGENIC MICE OVEREXPRESSING FOUR-REPEAT HUMAN TAU PROTEIN" AMERICAN JOURNAL OF PATHOLOGY,PHILADELPHIA, PA,US, vol. 155, no. 6, December 1999 (1999-12), pages 2153-2165, XP000974569 ISSN: 0002-9440 *
SPITTAELS K, ET AL.: "Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice" J BIOL CHEM. , vol. 275, no. 52, 29 December 2000 (2000-12-29), pages 41340-41349, XP002175365 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
US7265259B2 (en) 2000-05-18 2007-09-04 Consejo Superior De Investigaciones Clentificas GSK-3β expressed in a transgenic mouse
WO2001088109A3 (fr) * 2000-05-18 2002-07-04 Consejo Superior Investigacion Modele de maladie neurodegenerative
WO2001088109A2 (fr) * 2000-05-18 2001-11-22 Consejo Superior De Investigaciones Cientificas Modele de maladie neurodegenerative
WO2002063951A2 (fr) * 2001-02-09 2002-08-22 University Of Florida Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique
WO2002063951A3 (fr) * 2001-02-09 2004-03-04 Univ Florida Modelisation de maladies chez l'homme a l'aide d'un transfert de gene somatique
US9518284B2 (en) 2001-02-15 2016-12-13 The University Of Chicago Yeast screens for treatment of human disease
US8039209B2 (en) 2001-02-15 2011-10-18 The University Of Chicago Yeast screens for treatment of human disease
WO2002068663A1 (fr) * 2001-02-26 2002-09-06 Nv Remynd Modele de tau-opathie
WO2003046172A3 (fr) * 2001-11-09 2003-07-17 Univ London Modele de maladie
WO2003046172A2 (fr) * 2001-11-09 2003-06-05 University College London Modele de maladie
WO2004007722A3 (fr) * 2002-07-12 2004-03-25 Axon Neuroscience Animal transgenique exprimant la proteine tau de la maladie d'alzheimer
WO2004007722A2 (fr) * 2002-07-12 2004-01-22 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh Animal transgenique exprimant la proteine tau de la maladie d'alzheimer
KR20150145201A (ko) 2014-06-17 2015-12-29 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도

Also Published As

Publication number Publication date
NO20020010D0 (no) 2002-01-02
AU782281B2 (en) 2005-07-14
NO20020010L (no) 2002-01-02
AU6267300A (en) 2001-01-22
IL147406A0 (en) 2002-08-14
NZ515956A (en) 2004-04-30
JP2003504015A (ja) 2003-02-04
EP1216297A2 (fr) 2002-06-26
CA2372742A1 (fr) 2001-01-11
WO2001002552A3 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
Von Koch et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice
JPH07132033A (ja) アルツハイマー病モデルトランスジェニック動物
US7161060B1 (en) Transgenic mice comprising a genomic human tau transgene
AU782281B2 (en) Transgenic animals as models for neurodegenerative disease
JP2023104002A (ja) エクソンヒト化マウス
RU2266002C2 (ru) Способ получения отличного от человека животного с мутированным нокин-геном, способ тестирования вещества на применимость для лечения болезни альцгеймера (варианты), плазмида (варианты), способ получения первичной культуры клеток или субкультивируемой клетки
JP5070236B2 (ja) 神経変性性障害のトランスジェニック動物モデル
Loring et al. Rational design of an animal model for Alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent
US7767879B2 (en) Transgenic animal model of neurodegenerative disorders
US5777194A (en) Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US20060168673A1 (en) Transgenic animals as models for neurodegenerative disease
ZA200110477B (en) Transgenic animals as models for neurodegenerative disease.
AU2001262482B2 (en) Model for neurodegenerative disease
CA2295861C (fr) Methode de preparation d'un animal transgenique non-humain exprimant le p25
AU2001262482A1 (en) Model for neurodegenerative disease
CA2814737C (fr) Utilisation de peptide beta-42 pour reduire une deficience cognitive chez un sujet
JP2002142610A (ja) Ａｌｓモデルラット
Hernández Pérez et al. Model for neurodegenerative diseases
Von Koch Molecular analysis of a homologue of the mouse beta-amyloid precursor protein, APLP2: Isolation of APLP2cDNA, characterization of the APLP2 gene promoter and gene targeting of APLP2
MXPA00001318A (en) Transgenic animals expressing human p25
CA2468453A1 (fr) Methode de preparation d'un animal transgenique non-humain exprimant le p25

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 515956

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000949241

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020017016189

Country of ref document: KR

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001/10477

Country of ref document: ZA

Ref document number: 200110477

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2372742

Country of ref document: CA

Ref country code: CA

Ref document number: 2372742

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10030308

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 62673/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020017016189

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000949241

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 62673/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017016189

Country of ref document: KR